183 related articles for article (PubMed ID: 16673496)
1. Detectable viral loads and slow development of resistance.
Gadd C
IAPAC Mon; 2005 Oct; 11(10):295-6. PubMed ID: 16673496
[No Abstract] [Full Text] [Related]
2. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
[TBL] [Abstract][Full Text] [Related]
3. Evolution of protease and reverse transcriptase inhibitor resistance-associated mutations in HIV-1-infected protease inhibitor-treated patients with persistent low viraemia.
Duval X; Descamps D; Breton G; Darmon S; Ecobichon JL; Delarue S; Peytavin G; Leport C; Vildé JL; Brun-Vézinet F
Antivir Ther; 2005; 10(1):197-9. PubMed ID: 15751779
[No Abstract] [Full Text] [Related]
4. Resistance to anti-HIV medications.
Munk B
Posit Aware; 2002; 13(6):32-5. PubMed ID: 12484334
[No Abstract] [Full Text] [Related]
5. Antiretroviral resistance.
Geretti AM
J HIV Ther; 2006 Dec; 11(4):72-3. PubMed ID: 17578209
[No Abstract] [Full Text] [Related]
6. Resistance: what are the implications for treatment?
Alcorn K
IAPAC Mon; 2004 Mar; 10(3):76. PubMed ID: 15108677
[No Abstract] [Full Text] [Related]
7. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients.
Masciotra S; Garrido C; Youngpairoj AS; McNulty A; Zahonero N; Corral A; Heneine W; de Mendoza C; García-Lerma JG
AIDS; 2007 Nov; 21(18):2503-11. PubMed ID: 18025887
[TBL] [Abstract][Full Text] [Related]
8. Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen.
Doualla-Bell F; Avalos A; Gaolathe T; Mine M; Gaseitsiwe S; Ndwapi N; Novitsky VA; Brenner B; Oliveira M; Moisi D; Moffat H; Thior I; Essex M; Wainberg MA
Antimicrob Agents Chemother; 2006 Jun; 50(6):2210-3. PubMed ID: 16723586
[TBL] [Abstract][Full Text] [Related]
9. The clinical significance of viral fitness.
Geretti AM
J HIV Ther; 2005 Mar; 10(1):6-10. PubMed ID: 15951728
[TBL] [Abstract][Full Text] [Related]
10. HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
Uy J; Brooks JT; Baker R; Hoffman M; Moorman A; Novak R;
Antivir Ther; 2007; 12(6):957-62. PubMed ID: 17926650
[TBL] [Abstract][Full Text] [Related]
11. Virologic and immunologic responses to antiretroviral therapy among HIV-1 and HIV-2 dually infected patients: case reports from Abidjan, Côte d'Ivoire.
Borget MY; Diallo K; Adje-Toure C; Chorba T; Nkengasong JN
J Clin Virol; 2009 May; 45(1):72-5. PubMed ID: 19375979
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral rounds. Resistance: what you don't know--can it hurt you?
Gathe JC; Elion R
AIDS Clin Care; 2008 Jun; 20(6):51-2. PubMed ID: 18661634
[No Abstract] [Full Text] [Related]
13. Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children.
Delaugerre C; Warszawski J; Chaix ML; Veber F; Macassa E; Buseyne F; Rouzioux C; Blanche S
J Med Virol; 2007 Sep; 79(9):1261-9. PubMed ID: 17607781
[TBL] [Abstract][Full Text] [Related]
14. Researchers find that Texas clinic's HIV resistance is stable over time. Clinic's population shifts to more Hispanics.
AIDS Alert; 2007 Jan; 22(1):5-6. PubMed ID: 17722340
[No Abstract] [Full Text] [Related]
15. Resistance: a shifting paradigm.
Jenny-Avital ER
AIDS Clin Care; 2002 Dec; 14(12):106. PubMed ID: 12510656
[No Abstract] [Full Text] [Related]
16. Antiretroviral rounds. Putting resistance to work.
Daar ES; Elion R
AIDS Clin Care; 2004 Jul; 16(7):56, 60. PubMed ID: 15300926
[No Abstract] [Full Text] [Related]
17. Clinical implications of virological "failure": interview with Steven Deeks, M.D., San Francisco General Hospital. Interview by John S. James.
Deeks S
AIDS Treat News; 1998 Feb; (No 289):1-6. PubMed ID: 11365047
[TBL] [Abstract][Full Text] [Related]
18. Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy.
Jlizi A; Ben Ammar El Gaaied A; Slim A; Tebourski F; Ben Mamou M; Ben Chaabane T; Letaief-Omezzine A; Chakroun M; Garbouj M; Ben Rejeb S
Arch Virol; 2008; 153(6):1103-8. PubMed ID: 18483694
[TBL] [Abstract][Full Text] [Related]
19. The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation.
Zhang M; Han XX; Cui WG; Jia MH; Meng XD; Xing AH; Wu YH; Yang YY; Lu CM; Hu QH; Dai D; Zhang ZN; Shang H
Jpn J Infect Dis; 2008 Sep; 61(5):361-5. PubMed ID: 18806342
[TBL] [Abstract][Full Text] [Related]
20. Development of antiretroviral drug resistance.
Wainberg MA; Zaharatos GJ; Brenner BG
N Engl J Med; 2011 Aug; 365(7):637-46. PubMed ID: 21848464
[No Abstract] [Full Text] [Related]
[Next] [New Search]
